Andrew B. Lassman
About
Andrew B. Lassman is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Andrew B. Lassman has authored 191 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Genetics, 80 papers in Pulmonary and Respiratory Medicine and 56 papers in Oncology. Recurrent topics in Andrew B. Lassman's work include Glioma Diagnosis and Treatment (149 papers), Brain Metastases and Treatment (67 papers) and Cancer, Hypoxia, and Metabolism (27 papers). Andrew B. Lassman is often cited by papers focused on Glioma Diagnosis and Treatment (149 papers), Brain Metastases and Treatment (67 papers) and Cancer, Hypoxia, and Metabolism (27 papers). Andrew B. Lassman collaborates with scholars based in United States, Netherlands and Australia. Andrew B. Lassman's co-authors include Lisa M. DeAngelis, Patrick Y. Wen, Mark R. Gilbert, Timothy F. Cloughesy, Martin J. van den Bent, Kathleen R. Lamborn, David A. Reardon, Lauren E. Abrey, Michael A. Vogelbaum and Susan M. Chang and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.
In The Last Decade
Andrew B. Lassman
185 papers receiving 8.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrew B. Lassman United States | 44 | 5.8k | 3.0k | 2.1k | 2.0k | 1.9k | 191 | 8.8k | ||
| Olivier Chinot France | 52 | 7.5k 1.3× | 3.3k 1.1× | 2.2k 1.0× | 1.7k 0.8× | 3.1k 1.6× | 296 | 11.7k | ||
| Michael A. Vogelbaum United States | 55 | 8.1k 1.4× | 4.1k 1.4× | 2.6k 1.2× | 3.2k 1.6× | 2.0k 1.1× | 239 | 12.8k | ||
| Enrico Franceschi Italy | 38 | 4.1k 0.7× | 2.0k 0.7× | 1.2k 0.6× | 1.1k 0.6× | 1.4k 0.7× | 193 | 5.8k | ||
| Annick Desjardins United States | 51 | 6.3k 1.1× | 2.2k 0.7× | 2.6k 1.3× | 1.0k 0.5× | 3.2k 1.7× | 247 | 10.0k | ||
| David R. Macdonald Canada | 34 | 8.1k 1.4× | 3.2k 1.1× | 970 0.5× | 2.8k 1.4× | 1.8k 1.0× | 77 | 9.7k | ||
| Randy L. Jensen United States | 45 | 3.7k 0.6× | 1.6k 0.5× | 1.3k 0.6× | 947 0.5× | 2.1k 1.1× | 202 | 7.6k | ||
| Ryo Nishikawa Japan | 40 | 4.3k 0.7× | 1.7k 0.6× | 2.1k 1.0× | 959 0.5× | 3.3k 1.7× | 201 | 8.4k | ||
| Manmeet S. Ahluwalia United States | 49 | 4.6k 0.8× | 4.4k 1.5× | 3.8k 1.8× | 1.1k 0.5× | 1.9k 1.0× | 398 | 9.6k | ||
| P Farah Lebanon | 5 | 5.8k 1.0× | 2.0k 0.7× | 1.2k 0.6× | 1.3k 0.7× | 3.1k 1.6× | 8 | 10.2k | ||
| Ahmed Idbaïh France | 48 | 5.4k 0.9× | 1.8k 0.6× | 1.2k 0.6× | 1.4k 0.7× | 3.4k 1.8× | 259 | 9.7k |
Countries citing papers authored by Andrew B. Lassman
Since
Specialization
Citations
This map shows the geographic impact of Andrew B. Lassman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew B. Lassman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew B. Lassman more than expected).
Fields of papers citing papers by Andrew B. Lassman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrew B. Lassman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew B. Lassman. The network helps show where Andrew B. Lassman may publish in the future.
Co-authorship network of co-authors of Andrew B. Lassman
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew B. Lassman. A scholar is included among the top collaborators of Andrew B. Lassman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew B. Lassman. Andrew B. Lassman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Groot, John Frederick De, Timothy F. Cloughesy, Donald A. Berry, et al.. (2024). Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2005–2005.
2.
Merrell, Ryan, Patrick Y. Wen, Deborah Forst, et al.. (2024). Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.. Journal of Clinical Oncology. 42(16_suppl). TPS2100–TPS2100.
3.
Arrillaga‐Romany, Isabel, Andrew B. Lassman, Susan L. McGovern, et al.. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology. 26(Supplement_2). S173–S181.
4.
Arrillaga‐Romany, Isabel, Andrew B. Lassman, Susan L. McGovern, et al.. (2023). P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA. Neuro-Oncology. 25(Supplement_2). ii84–ii84.
5.
Mair, Maximilian J., Rupert Bartsch, Émilie Le Rhun, et al.. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology. 20(6). 372–389.
6.
Ellingson, Benjamin M., Patrick Y. Wen, Susan M. Chang, et al.. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology. 25(6). 1017–1028.
7.
Iwamoto, Fábio M., Neel I. Nissen, David A. Reardon, et al.. (2023). CTIM-27. PERIPHERAL BIOMARKER ANALYSIS OF T CELL-MEDIATED COLLAGEN REMODELING CORRELATES WITH TUMOR RESPONSES IN A PHASE IIA TRIAL OF VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology. 25(Supplement_5). v68–v68.
8.
Rudà, Roberta, David Capper, Adam Waldman, et al.. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncology. 24(12). 2015–2034.
9.
Lassman, Andrew B., Khê Hoang‐Xuan, Mei‐Yin C. Polley, et al.. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology. 40(23). 2539–2545.
10.
Kumthekar, Priya, Michael J. Avram, Andrew B. Lassman, et al.. (2022). A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncology. 25(3). 557–565.
11.
Lassman, Andrew B., Patrick Y. Wen, Martin J. van den Bent, et al.. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research. 28(3). 452–460.
12.
Mohile, Nimish, Hans Messersmith, Na Tosha Gatson, et al.. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology. 24(3). 358–383.
13.
Hillyer, Grace Clarke, Melissa Beauchemin, Dawn L. Hershman, et al.. (2020). Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients. Clinical Trials. 17(2). 184–194.
14.
Lassman, Andrew B., et al.. (2020). Current usage of tumor treating fields for glioblastoma. Neuro-Oncology Advances. 2(1). vdaa069–vdaa069.
15.
Lassman, Andrew B., Lisa Roberts-Rapp, И. А. Соколова, et al.. (2019). Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research. 25(11). 3259–3265.
16.
Groot, John de, Kathleen R. Lamborn, Susan M. Chang, et al.. (2011). Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology. 29(19). 2689–2695.
17.
Groot, John de, Yuji Piao, Hai T. Tran, et al.. (2011). Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research. 17(14). 4872–4881.
18.
Clarke, Jennifer, Fábio M. Iwamoto, Joohee Sul, et al.. (2009). Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 27(23). 3861–3867.
19.
Shapiro, Lauren, Sasan Karimi, Philip H. Gutin, et al.. (2009). Patterns of Failure Following Concurrent Bevacizumab and Hypofractionated Stereotactic Radiotherapy for Recurrent High-grade Glioma. International Journal of Radiation Oncology*Biology*Physics. 75(3). S125–S125.
20.
Lassman, Andrew B., Michael R. Rossi, Lauren E. Abrey, et al.. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research. 11(21). 7841–7850.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Olivier Chinot Breakdown of academic impact, for papers by Michael A. Vogelbaum Breakdown of academic impact, for papers by Enrico Franceschi Breakdown of academic impact, for papers by Annick Desjardins Breakdown of academic impact, for papers by David R. Macdonald Breakdown of academic impact, for papers by Randy L. Jensen Breakdown of academic impact, for papers by Ryo Nishikawa Breakdown of academic impact, for papers by Manmeet S. Ahluwalia Breakdown of academic impact, for papers by P Farah Breakdown of academic impact, for papers by Ahmed Idbaïh